 EMERYVILLE, Calif., Sept. 24, 2021 GLOBE NEWSWIRE -- Gritstone bio, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the companys Board of Directors has granted six employees nonqualified stock options to purchase an aggregate of 41,800 shares of its common stock with an exercise price of 11.58, which is equal to the closing price of Gritstones common stock on September 14, 2021, the grant date of the awards. These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635c4. 